-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 22, Tessa Therapeutics announced the appointment of Thomas Willemsen as its president and chief executive officer, effective October 1, 2022, as well as his appointment to the company's board of directors
Willemsen said: "Tessa is at the forefront of developing next-generation CAR-T therapies, as demonstrated in Phase I/II clinical trials of CD30 with allogeneic 'off the shelf' EBVST technology
.
I look forward to working with the entire Tessa team.
Working together, we will continue to make positive progress in the CAR-T program and ultimately bring these important therapies to patients with unmet medical needs
.
"